Plain-English translation of NCT06064097 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether adding , an immunotherapy drug that helps your immune system fight cancer, to standard chemotherapy can work better for nasopharyngeal cancer in young people. The study combines two chemotherapy drugs ( and ) with this medication, followed by radiation therapy and ongoing treatment with the medication. Researchers want to see if this combination is safe and whether it helps patients live longer without their cancer returning.
Nasopharyngeal cancer in young people is rare but serious, and current treatments don't work for everyone. This medication works differently than traditional chemotherapy by training your body's immune system to recognize and attack cancer cells, which might improve outcomes when combined with standard chemotherapy.
You likely qualify if…
You likely don't qualify if…
You would receive chemotherapy combined with the immunotherapy medication through IV infusions, followed by radiation therapy targeting your cancer, and then continue the medication alone for several months as maintenance treatment. Throughout the study, you'll have regular blood tests, imaging scans, and doctor visits to monitor how well the treatment is working and watch for side effects. The entire treatment period typically lasts several months, with follow-up visits continuing for years to track your long-term health.
AI-generated summary from trial data · Sep 20, 2026 · Not medical advice
United States